BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 15004663)

  • 1. The comparison of radiotherapy techniques for treatment of the prostate cancer: the three-field vs. the four-field.
    Milecki P; Piotrowski T; Dymnicka M
    Neoplasma; 2004; 51(1):64-9. PubMed ID: 15004663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
    Luxton G; Hancock SL; Boyer AL
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial for the optimisation of treatment position in the radiation therapy of prostate cancer.
    O'Neill L; Armstrong J; Buckney S; Assiri M; Cannon M; Holmberg O
    Radiother Oncol; 2008 Jul; 88(1):61-6. PubMed ID: 18453021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy.
    Mock U; Bogner J; Georg D; Auberger T; Pötter R
    Strahlenther Onkol; 2005 Jul; 181(7):448-55. PubMed ID: 15995838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose distribution in 3-dimensional conformal radiotherapy for prostate cancer: comparison of two treatment techniques (six coplanar fields and two dynamic arcs).
    Jereczek-Fossa BA; Cattani F; D'Onofrio A; Cambria R; Kowalczyk A; Corallo A; Vavassori A; Zerini D; Ivaldi GB; DeCobelli O; Orecchia R
    Radiother Oncol; 2006 Dec; 81(3):294-302. PubMed ID: 17113670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk.
    Fenoglietto P; Laliberte B; Allaw A; Ailleres N; Idri K; Hay MH; Moscardo CL; Gourgou S; Dubois JB; Azria D
    Radiother Oncol; 2008 Jul; 88(1):77-87. PubMed ID: 18215434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients.
    Kassim I; Dirkx ML; Heijmen BJ
    Radiother Oncol; 2009 Jul; 92(1):62-7. PubMed ID: 19278745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the optimal co-planar field arrangement for use in the boost phase of dose escalated conformal radiotherapy for localized prostate cancer.
    Khoo VS; Bedford JL; Webb S; Dearnaley DP
    Br J Radiol; 2001 Feb; 74(878):177-82. PubMed ID: 11718391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy of prostate cancer with multileaf collimators (MLCs) optimization of the undulating dose distribution at the MLC edge.
    Koelbl O; Schwab F; Bratengeier K; Vordermark D; Flentje M
    Strahlenther Onkol; 2005 Feb; 181(2):108-12. PubMed ID: 15702299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of supine vs. prone positioning in patients undergoing escalated dose conformal radiotherapy for prostate cancer.
    Bayley AJ; Catton CN; Haycocks T; Kelly V; Alasti H; Bristow R; Catton P; Crook J; Gospodarowicz MK; McLean M; Milosevic M; Warde P
    Radiother Oncol; 2004 Jan; 70(1):37-44. PubMed ID: 15036850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplified intensity-modulated arc therapy for dose escalated prostate cancer radiotherapy.
    Bauman G; Gete E; Chen JZ; Wong E
    Med Dosim; 2004; 29(1):18-25. PubMed ID: 15023389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
    Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of spatial dose gradients and probability density function to evaluate the effect of internal organ motion for prostate IMRT treatment planning.
    Jiang R; Barnett RB; Chow JC; Chen JZ
    Phys Med Biol; 2007 Mar; 52(5):1469-84. PubMed ID: 17301465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative radiation treatment for rectal cancer: comparison of target coverage and small bowel NTCP in conventional vs. 3D-conformal planning.
    Cella L; Ciscognetti N; Martin G; Liuzzi R; Punzo G; Solla R; Farella A; Salvatore M; Pacelli R
    Med Dosim; 2009; 34(1):75-81. PubMed ID: 19181259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of using biologic parameters (EUD and NTCP) in IMRT optimization for treatment of intrahepatic tumors.
    Thomas E; Chapet O; Kessler ML; Lawrence TS; Ten Haken RK
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):571-8. PubMed ID: 15890602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the conventional 'box technique' with two different 'conformal' beam arrangements for prostate cancer treatment.
    Magrini SM; Cellai E; Rossi F; Pertici M; Compagnucci A; Biti GP
    Cancer Radiother; 1999; 3(3):215-20. PubMed ID: 10394339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiobiological impact of reduced margins and treatment technique for prostate cancer in terms of tumor control probability (TCP) and normal tissue complication probability (NTCP).
    Jensen I; Carl J; Lund B; Larsen EH; Nielsen J
    Med Dosim; 2011; 36(2):130-7. PubMed ID: 20488692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dosimetric analysis of radiotherapy with middle shielding blocks of different widths at the lower cervical supraclavicular field for stage N2-3 nasopharyngeal carcinoma].
    Li FM; Luo W; He ZC; Zhang L; Sun Y; Qin WJ; Lu LX; Han F; Liu XQ; Liu MZ
    Ai Zheng; 2007 Oct; 26(10):1127-32. PubMed ID: 17927886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.